Tome Biosciences IPO

Tome Biosciences is a genomic medicine company. By creating programmable gene insertion technology, Tome Biosciences has a mission to deliver patients a cure with cell technology. The company’s integrative gene therapies work by destroying deoxyribonucleic acid and inserting a genetic sequence at any location of any size. Tome Biosciences was founded by Jonathan Gootenberg and Omar Abudayyeh in 2021 and is headquartered in Boston, MA.

Buy or sell Tome Biosciences stock Learn more about Tome Biosciences stock

Learn more about Tome Biosciences

Is Tome Biosciences a publicly traded company?

Tome Biosciences is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Will Tome Biosciences go IPO?

Tome Biosciences has not yet filed for an IPO. However, it's important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or through mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is Tome Biosciences's IPO price?

The IPO price for Tome Biosciences will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.

Can you invest in Tome Biosciences pre-IPO?

Tome Biosciences is privately held company and is not publicly traded, therefor investing in Tome Biosciences pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to invest in private companies before their potential IPO. If you are not an accredited investor, discover how to begin the the process to potentially qualify for new investment opportunities.

What is the value of my Tome Biosciences shares?

To determine the value of your Tome Biosciences shares, create a free account to gain access to Forge’s platform. Forge Markets contains pricing information for hundreds of pre-IPO companies. A Private Market Specialist will also be available to assist you with any inquiries related to your Tome Biosciences shares. You can also learn more about how to sell your private shares before getting started.

Can you sell Tome Biosciences before it goes public?

Yes, you can seek to sell shares in Tome Biosciences while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is Tome Biosciences's funding to date?

Tome Biosciences has raised $245.57MM to date.

When was Tome Biosciences founded?

Tome Biosciences was founded in 2021.

Who are Tome Biosciences's major investors?

Andreessen Horowitz

Polaris Partners

Longwood Fund

Arch Venture Partners

Alexandria Venture Investments

Tome Biosciences funding rounds and last known valuation

Date	Funding Round	Funding Raised	Price per Share	Last Known Valuation
12/12/2023	Series B	$150MM raised	$XXX.XX	$XXX.XX
1/15/2022	Series A and A-2	$95.57MM raised	$XXX.XX	$XXX.XX

Based on primary financings

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.